Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AdvaMed wants full recognition of ISO 13485

This article was originally published in The Silver Sheet

Executive Summary

Device trade association AdvaMed is urging FDA to move more quickly to fully recognize ISO 13485, the international quality system standard for medical device manufacturing. "We believe it would be good ... for FDA to recognize ISO 13485 because companies operate in a global environment," Janet Trunzo, AdvaMed's executive VP of technology and regulatory affairs, told "The Silver Sheet." "Because quality system management programs are such an integral part of medical device manufacturing, the safety and effectiveness of medical devices is not dependent on FDA and the frequency of FDA inspections," she said. Inspections are "a core function of FDA, but the quality management systems and compliance to ISO 13485 ... also is a very important part of a company's programs." ISO 13485's requirements for firms are not identical to the Quality System Regulation, although the two regimes are "95 percent alike," Trunzo noted. The agency recently released a draft guidance that would allow the results of ISO inspections to be a factor in FDA's decision whether to conduct its own inspections ("The Silver Sheet" June 2010)

You may also be interested in...

Bio-Thera Gets Chinese Nod To Proceed On Ustekinumab

China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.

Can Synthetic CBD Overcome Cannabis Stigma And Break EU Novel Foods Deadlock?

Czech firm CBDepot has filed a novel food application for synthetically made CBD in Europe, which it hopes regulators will find more palatable than those for supplements derived from the cannabis plant.

Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?

A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts